UroGen Pharma financials
$40.45−1.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M | $11.8M | $18.0K | $1.1M | $8.2M |
| Gross profit | $97.3M | $81.5M | $73.4M | $48.3M | $42.9M | $10.8M | $18.0K | -$675.0K | $7.6M |
| Gross margin | 88.7% | 90.2% | 88.7% | 75.0% | 89.3% | 91.4% | 100.0% | −59.8% | 92.6% |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$87.5M | -$92.3M | -$126.7M | -$109.5M | -$77.2M | -$19.9M |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M | -$110.8M | -$128.5M | -$105.1M | -$75.7M | -$20.8M |
| Net margin | −139.8% | −140.4% | −123.6% | −170.6% | −230.7% | −1088.9% | −584144.4% | −6707.2% | −255.3% |
| Diluted EPS | $-3.19 | $-2.96 | $-3.55 | $-4.81 | $-4.96 | $-5.90 | $-5.12 | $-4.80 | $-2.14 |
| EBITDA | -$124.6M | -$96.5M | -$64.7M | -$85.7M | -$91.5M | -$124.7M | -$109.2M | -$76.8M | -$19.7M |
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M | -$84.9M | -$105.9M | -$71.0M | -$37.3M | -$9.6M |
| Free cash flow | -$162.7M | -$97.1M | -$76.6M | -$87.8M | -$85.6M | -$107.1M | -$71.3M | -$37.9M | -$9.8M |
| Diluted shares | 48.1M | 42.9M | 28.8M | 22.8M | 22.3M | 21.8M | 20.5M | 15.8M | 9.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.7M | $172.0M | $95.0M | $55.4M | $44.4M | $52.9M |
| Short-term investments | $9.7M | $64.7M | $42.0M | $44.6M | $44.8M | $49.2M |
| Total debt | $127.0M | $121.7M | $98.6M | $97.5M | $0.00 | $0.00 |
| Total assets | $200.5M | $285.7M | $178.3M | $135.6M | $119.7M | $122.0M |
| Total liabilities | $305.9M | $294.5M | $243.5M | $225.0M | $111.3M | $25.6M |
| Shareholders' equity | -$105.5M | -$8.8M | -$65.2M | -$89.4M | $8.4M | $96.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology